Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...

NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now ...

I’m bullish on Novo Nordisk based on its suddenly appealing valuation, consistent track record as a dividend stock, and long-term history of outperforming the market. For patient investors ...

The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Novo’s experimental ...

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...